great end must med-tech name reiter ow
even report financi result outperform pre-
announc januari quarter perform robust across
geographi result increas patient type type compani re-
affirm guidanc absolut basi repres growth
mid-point like conserv given manag track record look forward
encourag opportun see non-intens patient
popul believ repres patient alon addit
remain track full commerci launch manufactur capac
improv allow invest dtc quit clearli lot
momentum across organ view remain bullish
outlook reiter ow rate increas pt
revenu outperform pre-announc januari
y/i difficult comp top line perform result continu
momentum domest y/i abroad y/i
busi benefit new patient addit across type type gross
margin quarter impress highest level sinc
line expect laid last quarter adjust ep beat
estim import thing note leverag deliv
someth believ sustain
guidanc compani reiter revenu guidanc absolut
basi result better expect perform
growth rate tad lower year addit
year compani anticip gross margin adjust ebitda margin
adjust oper margin guidanc contempl strong
patient volum increas full roll-out medicar patient addit ou region
introduct on-going pharmaci channel custom access initi
previous state averag revenu per patient expect declin result
thought us key compon earn call manag
commentari around opportun repres non-intens type patient
compani remain enthusiast ever outlook intens
patient acknowledg substanti opportun non-intens
patient popul repres continu next page
develop continu glucos monitor diabet manag
net cash fulli dilut share
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
thought continu ask manag team call compani
state go non-intens patient around
world encourag hear could materi significantli begin
enter though want put cart hors anoth
import factor move beyond manufactur capac improv made
year compani doubl manufactur capac plan
provid cost save addit capac allow
invest dtc market significantli bolster new patient addit
front manag reiter previou timelin limit contribut year full launch
one last point mention leverag profit profil quickli
improv compani near long-term financi target put origin
expect achiev taken togeth think upsid profit long-
term attract proposit given impress top-lin growth rate deliv
stock follow even result expect share lift
meaning tomorrow said see one best open-end growth stori
medic technolog find hard expect compani under-perform especi
consid encourag trend hear channel check consequ view
must med-tech name rate stock ow roll forward multipl
base ev/sal assum net cash share
outstand prior premium peer group given dxcm
averag top-line growth price target increas
page
page
good gener incom expens net incom tax incom analysi gross gener breakdown durabl
thousand except per share
good sold
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
